Planta Med 2023; 89(13): 1204-1214
DOI: 10.1055/a-2114-0980
Biological and Pharmacological Activity
Original Papers

1-Methoxyerythrabyssin II Induces Autophagy in Leukemia Cells via PI3K/Akt/mTOR Pathways

Authors

  • Bo Fang

    1   College of Pharmacy, Wenzhou Medical University, Wenzhou, China
    2   Research Institute of Pharmaceutical Sciences, College of Pharmacy, Chonnam National University, Gwangju, Korea
  • Soeun Kim

    2   Research Institute of Pharmaceutical Sciences, College of Pharmacy, Chonnam National University, Gwangju, Korea
  • Yebon Kim

    2   Research Institute of Pharmaceutical Sciences, College of Pharmacy, Chonnam National University, Gwangju, Korea
  • Yinda Qiu

    1   College of Pharmacy, Wenzhou Medical University, Wenzhou, China
    2   Research Institute of Pharmaceutical Sciences, College of Pharmacy, Chonnam National University, Gwangju, Korea
  • Chang-Min Lee

    3   Department of Veterinary Internal Medicine, College of Veterinary Medicine and BK21 FOUR Program, Chonnam National University, Gwangju, Korea
  • Yinshuang Lai

    1   College of Pharmacy, Wenzhou Medical University, Wenzhou, China
  • Zhiguo Liu*

    1   College of Pharmacy, Wenzhou Medical University, Wenzhou, China
  • Kun Wang*

    1   College of Pharmacy, Wenzhou Medical University, Wenzhou, China
  • Namki Cho*

    2   Research Institute of Pharmaceutical Sciences, College of Pharmacy, Chonnam National University, Gwangju, Korea

This research was supported by a grant from the National Research Foundation (NRF) of Korea funded by the Korean government (MSIT) (grant number: NRF-2022R1C1C1009626). In addition, this work was supported by the National Research Foundation of Korea (NRF) grant funded by the Korea government (MSIT) under grant number 2022R1F1A1 059 721.

Abstract

Leukemia, despite currently being one of the most lethal cancers worldwide, still lacks a focused treatment. The purpose of the present investigation was to evaluate the pharmacological effect of 1-methoxyerythrabyssin II, a pterocarpan identified in the roots of Lespedeza bicolor, on leukemic cells and to explore its underlying mechanism using a network pharmacology strategy. 1-Methoxyerythrabyssin II showed an antiproliferative effect in a concentration-dependent manner and exhibited a higher potency in human acute leukemia T cells (Jurkat). The G1 phase arrest induced by 1-methoxyerythrabyssin II was confirmed using a cell cycle assay, and the downregulation of CDK2 and cyclin D1 was observed using an immunoblot assay. Moreover, 1-methoxyerythrabyssin II-treated cells exhibited higher expression levels of LC3B, Atg-7, and Beclin 1 in addition to an enhanced fluorescence intensity in monodansylcadaverine staining, indicating autophagy induction by 1-methoxyerythrabyssin II. Furthermore, network pharmacology and molecular docking analyses revealed that the PI3K/Akt/mTOR pathway is a potential target of 1-methoxyerythrabyssin II in leukemic cells. In vitro assays further demonstrated that 1-methoxyerythrabyssin II promoted autophagy and suppressed cell proliferation by inhibiting the PI3K/Akt/mTOR pathway in leukemic cells. This discovery will contribute to the development of novel therapeutics and prophylactics against leukemia.

* Co-corresponding authors.


Supporting Information



Publication History

Received: 25 July 2022

Accepted after revision: 13 June 2023

Article published online:
17 July 2023

© 2023. Thieme. All rights reserved.

Georg Thieme Verlag KG
Rüdigerstraße 14, 70469 Stuttgart, Germany